Management Announcement Regarding Business Update
SIGA Technologies, Inc. (SIGA), a leader in pharmaceutical development, has exciting news to share with its stakeholders. The management team will hold a business update call on Tuesday, August 5, 2025, at 4:30 P.M. ET. This event promises to provide valuable insights into the company’s recent achievements and future initiatives. Key executives, including CEO Diem Nguyen and CFO Daniel Luckshire, will be present during the call, bringing their expertise and strategies into focus.
How to Join the Call
If you're interested in joining this informative session, SIGA Technologies encourages participants to log on approximately 5-10 minutes before the scheduled start time. A live webcast will be accessible through the SIGA website in the Investor Relations section. Be sure to mark your calendars for this opportunity to hear directly from the leadership team.
Accessing the Conference Call
For those who prefer to dial in, participants may reach the call by calling 1-800-717-1738 for domestic callers or 1-646-307-1865 for international attendees. This gives both local and global audiences a chance to engage in real-time discussions and inquiries regarding SIGA’s business updates.
Replay Availability After the Call
Don't worry if you cannot attend the live call; a replay of the discussion will be available for two weeks. You can access the recorded version by calling 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers using Conference ID: 1130215. Additionally, the archived webcast will be posted on the SIGA website, ensuring that all stakeholders can stay informed.
About SIGA Technologies
SIGA Technologies is at the forefront of developing innovative medical solutions for critical health challenges. Their primary focus is on creating medicines for infectious diseases, particularly orthopoxviruses. Their flagship product, TPOXX (tecovirimat), is an antiviral medicine already approved in the U.S. and Canada for treating smallpox. It has also received authorization for use in Europe, the UK, and Japan for smallpox and other related diseases, including mpox. Through robust partnerships with public health sectors, SIGA strives to deliver essential countermeasures against global health threats.
Product Leadership in the Pharmaceutical Space
The company’s commitment to fighting severe infectious diseases plays a critical role in global health security. By focusing on advanced therapies, SIGA is not only responding to current health crises but also paving the way for future innovations. Their dedication to research and development showcases their role as a key player in the pharmaceutical industry.
Contact Information for Stakeholders
If you have any inquiries, you can reach out to Suzanne Harnett via email at sharnett@siga.com. For further assistance related to investments or media communication, Jennifer Drew-Bear from Edison Group (Jdrew-bear@edisongroup.com) and Holly Stevens from CG Life (hstevens@cglife.com) are available to assist.
Frequently Asked Questions
What is the purpose of the SIGA business update call?
The call aims to provide stakeholders with insights into SIGA Technologies' recent performance and upcoming initiatives directly from company leadership.
Who are the key executives participating in the call?
CEO Diem Nguyen and CFO Daniel Luckshire will present and provide updates during the call.
How can I access the live webcast?
Visit the SIGA Technologies website in the Investor Relations section to tune into the live webcast.
Will there be a replay of the call?
Yes, a replay will be available for two weeks after the call, accessible via a dedicated phone line or on the SIGA website.
What is the main focus of SIGA Technologies?
SIGA Technologies focuses on developing innovative medicines for infectious diseases, particularly those caused by orthopoxviruses, as part of their commitment to global health.
